Abstract library

82 results for "sstr".
#446 Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies
Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Herbert Schmid
#1415 Detection of SSTR2 and 5 Expression on Circulating Tumour Cells in Neuroendocrine Tumours
Introduction: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR) which can be targeted for therapy with somatostatin analogues (SSA) or radionuclide treatment.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: DR Alexa Childs
Authors: Childs A, Vesely C, Ensell L, Luong T, ...
Keywords: CTC, SSTR
#791 Quantification of Somatostatin Receptor Subtypes Using In Vivo PET/CT-Data, Ex Vivo Conventional Immunohistochemistry and Automated Digitized Analysis by Definiens XD Image Software
Introduction: Diagnostics and therapy of NET are significantly influenced by their somatostatin receptor (SSTR) status. Immunohistochemistry (IHC) of SSTR performed by pathologists is a time-consuming and cost-intensive procedure.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. med. Daniel Kaemmerer
Keywords: SSTR
#120 Somatostatin receptors 1-5 expression in a large series of well-differentiated neuroendocrine tumors
Introduction: For their antisecretive and antiproliferative effect somatostatin analogs (SA) have been used in the treatment of neuroendocrine tumors (NETs), based on the expression of somatostatin receptors (sstRs). The potential availability of new SA for the treatment of patients with NETs suggests a better characterization of sstRs.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Paola Loli
#1574 Somatostatin Receptors Profile in Pulmonary NETs Associated with DIPNECH
Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare entity characterised histologically by the proliferation of neuroendocrine cells along the distal bronchiolar epithelium, associated with small tumourlets and usually found in association with pulmonary carcinoid tumour. This can be clinically silent or may be associated with symptomatic obstructive bronchiolitis.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Aurelie Fabre
Authors: Ryan C, Fabre A, Di Capua D M, Swan N, ...
Keywords: SSTR, DIPNECH, carcinoid
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
#1915 Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro
Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Sebastian Krug
#183 Immunhistochemical Expression of Somatostatin Receptors in Gastroenteropancreatic Neuroendocrine Tumors Using IRS- and Her2-scoring Scheme
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are known for an overexpression of somatostatin receptors (SSTR). This finding has already gained importance in diagnostics and therapy of NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Luisa Peter
Authors: Peter L, Kaemmerer D, Lupp A, Saenger J, ...
#819 Immunohistochemical and Genomic Evidence for the Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance, as they represent potential targets for diagnosis and treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: George A Kanakis